NCT05393245

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Safety Profile of Tiotropium + Olodaterol Used as Maintenance Treatment in COPD Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 19,467 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The aim of this real world study is to assess the safety profile of tiotropium/olodaterol (Tio/Olo).

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

Type	Name	Description
DRUG	Tiotropium+Olodaterol	Tiotropium+Olodaterol
DEVICE	Spiolto Respimat	Spiolto Respimat Inhaler device
DRUG	Long-acting muscarinic antagonists (LAMAs)	Long-acting muscarinic antagonists (LAMAs)
DRUG	Long-acting β2-agonists (LABAs)	Long-acting β2-agonists (LABAs)

Timeline

• Start date: 2022-09-30
• Primary completion: 2022-12-07
• Completion: 2022-12-07
• First posted: 2022-05-26
• Last updated: 2024-12-04
• Results posted: 2024-12-04

Locations

1 site across 1 country: China